No studies have investigated whether race/ethnicity is associated with the recommended use of preoperative chemotherapy or subsequent outcomes in gastric cancer. To determine whether there is such an association, analyses of patients with gastric cancer in the National Cancer Data Base (NCDB) were performed. METHODS: Patients with clinical T2-4bN0-1M0 gastric adenocarcinoma, as defined by the eighth edition of the American Joint Committee on Cancer staging manual, who underwent gastrectomy from 2006 to 2014 were identified from the NCDB. Multiple logistic regression was conducted to examine factors associated with preoperative chemotherapy use. RESULTS: This study identified 16,945 patients who met the criteria, and 8286 of these patients (49%) underwent preoperative chemotherapy. The use of preoperative chemotherapy remarkably increased over the study period, from 34% in 2006 to 65% in 2014. Preoperative chemotherapy was more commonly used for cardia tumors than noncardia tumors (83% vs 44% in 2014). In a multivariable analysis, races and ethnicities other than non-Hispanic (NH) white race were associated with less frequent use of preoperative chemotherapy in comparison with NH whites after adjustments for social, tumor, and hospital factors. The insurance status and the education level mediated an enhanced effect of racial/ethnic disparities in preoperative chemotherapy use. The use of preoperative chemotherapy and radiation therapy was associated with reduced racial/ethnic disparities in overall survival. CONCLUSIONS: Racial/ethnic disparities in the use of preoperative chemotherapy and in outcomes exist among patients with gastric cancer in the United States. Efforts to improve the access to high-quality cancer care in minority groups may reduce racial disparities in gastric cancer in the United States. Cancer 2018;124:998
INTRODUCTION
Gastric cancer is one of the cancer types that demonstrate significant racial disparities in incidence and survival. In 2017 in the United States, the estimated incidence of gastric cancer is 28,000, and 10,960 deaths from gastric cancer are expected. 1 Gastric cancer is more common in males than females (incidence rate ratio, 2.0) and shows significant variability between racial/ethnic groups; the incidence rate in males is lowest among NH whites (7.8 per 100,000 persons) and higher among African Americans (14.7 per 100,000), Asians/Pacific Islanders (APIs; 14.4 per 100,000), and Hispanics (13.1 per 100,000). 1 Racial disparities are also widely reported in gastric cancer presentation, treatment, and survival outcomes in the United States. [2] [3] [4] [5] Using data from the National Cancer Data Base (NCDB; 1995-2002), Al-Refaie et al 3 reported that surgery combined with chemotherapy and radiation therapy was associated with improved survival in comparison with surgery alone for patients with gastric adenocarcinoma (hazard ratio, 0.80; P < .0001). However, African American patients were less likely to receive the combined therapy (P < .01) and had reduced survival rates (hazard ratio, 1.22; P < .0001) in comparison with other race groups. Similar results have been reported with data from the Surveillance, Epidemiology, and End Results program (1998) (1999) (2000) (2001) . 2 Several studies have shown that African Americans and NH whites have similar cancer-specific mortality rates if they receive identical cancer treatments, [6] [7] [8] and this suggests that racial/ethnic differences in tumor biology may be negligible if there is equal access to high-quality care. Whether high-quality cancer care is provided equally to all racial groups is, therefore, among the most important determinants of cancer outcomes in the United States.
Over the past 10 years, the treatment of gastric cancer has undergone a significant shift. After several large randomized controlled trials showed a survival benefit from perioperative chemotherapy in patients with resectable gastric cancer, [9] [10] [11] the use of preoperative chemotherapy in patients with resectable gastric cancer has sharply increased over the past 10 years, from 25.9% of patients with gastric cancer in 2003 to 46.3% in 2012. 12 The National Comprehensive Cancer Network guidelines recommend preoperative chemotherapy for patients with clinical T2-4b tumors without evidence of distant metastasis. 13 However, no studies have investigated whether race/ ethnicity is associated with the use of preoperative chemotherapy. The overall objectives of this study were to establish the extent of racial disparities and their changes over time and to describe factors that contribute to these disparities in the use of preoperative therapy in patients with gastric cancer. Our central hypothesis was that race/ethnicity is associated with impaired access to high-quality gastric cancer treatment and that the racial disparities are enhanced by various social factors. The specific aims of this study were 1) to describe the impact of race/ethnicity on the use of preoperative chemotherapy and trends in this use over time in clinical patients with T2-4bN0-1M0 gastric cancer in the United States and 2) to identify risk factors affecting the association between race/ethnicity and the use of preoperative chemotherapy by an analysis of patients with gastric cancer in the NCDB. Because race/ethnicity is closely and complexly related to various risk factors for unequal access to high-quality cancer treatment, such as socioeconomic status, education level, and insurance status, 14, 15 we carefully evaluated these factors and statistically adjusted for them. We also investigated racial/ethnic disparities in treatment outcomes.
MATERIALS AND METHODS

Study Design and Source of Data
The design of this study was a retrospective cohort study. We used data from the NCDB provided by the Commission on Cancer of the American College of Surgeons and the American Cancer Society. 16 Approximately 70% of all newly diagnosed cases of cancer in the United States are reported to the NCDB. 16 The institutional review boards at The University of Texas MD Anderson Cancer Center (protocol PA17-0325) and at The University of Texas Health Science Center at Houston School of Public Health (protocol HSC-SPH-17-0345) approved this study.
Patients
We identified patients with gastric adenocarcinoma according to International Classification of Diseases for Oncology codes C16.0 to C16.9; tumor histology codes 8140 (adenocarcinoma, not otherwise specified [NOS]), 8144 (adenocarcinoma, intestinal type), 8145 (adenocarcinoma, diffuse type), 8481 (mucin-producing adenocarcinoma), and 8490 (signet ring cell adenocarcinoma); and tumor behavior code 3 (invasive). We included men and women who were 18 years old or older without evidence of distant metastasis (clinical stage M0) who underwent gastrectomy, which was defined by surgical procedure codes 30 to 80 (gastrectomy, NOS; nearly total or total gastrectomy; gastrectomy, NOS with removal of a portion of the esophagus; and gastrectomy with resection in continuity with the resection of other organs, NOS), from 2006 to 2014. Treatment data for the years 2004 and 2005 were not included because the treatment sequence code was not available for those years. Patients with clinical T2-4b tumors, as defined by the eighth edition of the American Joint Committee on Cancer staging manual, were included; these patients represented the cohort recommended for preoperative chemotherapy. 13 
Study Variables
The main exposure variable was race/ethnicity, and the main outcome variable was preoperative chemotherapy use, which was defined by systemic therapy surgery sequence code 2 (systemic therapy given before surgery) or 4 (systemic therapy given before and after surgery). Other baseline patient/tumor characteristic variables that were collected included the age group (<45, 45-54, 55-64, or 65-75 years), sex (male or female), race/ethnicity (NH white, NH black, Hispanic, API, or other), comorbidity score (Charlson/Deyo score: 0-2), clinical T and N categories (as defined by the American Joint Committee on Cancer staging manual), location of the primary tumor (cardia, fundus/body, antrum/pylorus, or overlapping lesions), histology grade (well, moderately, or poorly differentiated or undifferentiated), type of treating institution (community cancer program, comprehensive community cancer program, academic/research cancer program, or other/unknown), insurance status (private insurance, Medicaid, Medicare, other public insurance, or no insurance), annual income (median household income in the ZIP code of residence: < $38,000, $38,000-$47,999, $48,000-$62,999, or $63,000), educational status (proportion of adults in the ZIP code of residence who did not graduate from high school: 21%, 13% to < 21%, 7% to < 13%, or < 7%), location of residence (metro, urban, or rural as defined by the population size of the county of residence), and treatment year period (2006-2008, 2009-2011, or 2012-2014) . Missing data were categorized as "unknown" for covariates. Patients with missing outcome variables were excluded from the specific analyses for which they lacked outcomes. The US census region was not included among the study variables because of the expected collinearity with race/ethnicity proportions. The use of preoperative radiation therapy was defined by radiation surgery sequence code 2 (radiation therapy given before surgery) or 4 (radiation therapy given before and after surgery). Short-term outcome variables in secondary analyses included the following: unexpected readmission within 30 days (code 1 [unplanned readmission within 30 days] or 3 [both planned and unplanned readmissions within 30 days]), length of the hospital stay, and 90-day mortality.
Statistical Analyses
Differences in patient/tumor characteristics by preoperative chemotherapy use were examined with chi-square tests for categorical variables and with t tests for continuous variables. Associations between factors and the use of preoperative chemotherapy were then examined by multiple logistic regression. 17 Annual income was not included in the model on account of its collinearity with education level because both variables were estimated with the ZIP code. Variables with P values less than .1 according to univariate analyses were included in the primary model, and then a stepwise method with backward elimination with a cutoff P value of .1 was used to create the reduced model. Interaction terms between race/ethnicity and treatment year period were added to the final model to test whether the association between race/ethnicity and preoperative chemotherapy use changed over time by a likelihood ratio test. A multiple logistic regression model was used to examine associations between preoperative chemotherapy and short-term outcomes adjusted for effects of the age group, race/ethnicity, treatment year period, comorbidity score, hospital type, clinical T category, clinical N category, and primary tumor location (cardia vs noncardia). A multiple Cox regression model was used to examine overall survival (OS), which was defined as the time in months from diagnosis to death or censored at the last contact. The age group, race/ethnicity, insurance status, education level, comorbidity score, hospital type, pathologic T category, pathologic N category, and primary tumor location (cardia vs noncardia) were included in the model because these variables were considered clinically important for predicting survival. Because interaction terms between races/ethnicities and preoperative therapy regimens (none vs chemotherapy alone vs chemotherapy and radiation therapy) were significant (P < .001 according to a likelihood ratio test), models were fit separately by preoperative therapy regimen. The treatment year was not included in the survival analysis because it created a significant difference in follow-up periods between strata. In addition, propensity-score matching was implemented to reduce the effects of factors other than race on the use of neoadjuvant chemotherapy. NH white patients were matched to "other" race patients with a ratio of 1:1, and then a conditional logistic regression model was fit to assess the association between race and neoadjuvant chemotherapy use (Supporting Information 1 [see online supporting information]). The fit of the multivariable logistic regression models was assessed by the calculation of the area under the receiver operating characteristic curve and standardized Pearson residual plots (Supporting Information 2 [see online supporting information]). For Cox regression models, the proportional hazards assumption was tested by proportional hazards testing and plotting of the log(-log) survival probability. Variables with P values less than .05 were considered significant. All statistical analyses were performed with Stata software (version 14.1; StataCorp, College Station, Texas).
RESULTS
We identified a total of 16,945 patients who met the study criteria, and 8286 of these patients (49%) underwent preoperative chemotherapy. The median age was 65 years (interquartile range, 57-74 years), and 69% were male; 71% were NH white, 12% were NH black, 9% were Hispanic, and 7% were API. Baseline patient/tumor characteristics according to the preoperative chemotherapy status are summarized in Table 1 .
Trends in Preoperative Chemotherapy Use Over Time
The use of preoperative chemotherapy in patients with gastric cancer increased remarkably over the study period, from 34% in 2006 to 65% in 2014. The use of preoperative chemotherapy significantly differed by tumor location (cardia vs noncardia). The increases remained remarkable after stratification by tumor location but were most prominent in patients with cardia tumors: 83% of the patients with cardia tumors but only 44% of the Original Article patients with noncardia tumors underwent preoperative chemotherapy in 2014 (Fig. 1) . Increasing preoperative chemotherapy use was observed in all race/ethnicity groups, and when these results were again stratified by tumor location, the difference between NH white race and other races disappeared in noncardia tumors (Supporting Fig. 1 [see online supporting information]). We also observed increasing preoperative chemotherapy use in all types of hospitals. Preoperative chemotherapy was more commonly used in academic cancer centers than other hospital types. This pattern remained in noncardia tumors after stratification by tumor location, whereas the difference among hospital types was notably smaller in cardia tumors (Supporting Fig. 2 [see online supporting information]).
Factors Associated With Preoperative Chemotherapy Use
The results of multivariable analyses of associations between patient, tumor, and hospital factors and preoperative chemotherapy use are summarized in Table 2 . In the multivariable analysis, the NH black (odds ratio, 0.76; 95% confidence interval [CI], 0.67-0.86; P < .001), Hispanic (odds ratio, 0.83; 95% CI, 0.72-0.95; P 5 .006), and API races/ethnicities (odds ratio, 0.62; 95% CI, 0.53-0.72; P < .001) were associated with less frequent use of preoperative chemotherapy in comparison with the NH white race/ethnicity. Among factors in the model, the insurance type, education level, and hospital type were notably associated with preoperative chemotherapy use ( Table 2) . A model including interaction terms between race/ethnicity groups and treatment year periods was tested, and the interaction terms were not statistically significant (P 5 .69 according to a likelihood test); increases in preoperative chemotherapy use over time were homogeneous between race/ethnicity groups. Figure 2 displays relations between race/ethnicity and preoperative chemotherapy use, including social and patient factors. Race/ethnicity other than NH white race was independently associated with less frequent use of preoperative chemotherapy (odds ratio, 0.72; 95% CI, 0.66-0.79; P < .001). In addition, race/ethnicity other than NH white race was associated with a low education level and no insurance status, each of which was also associated with less frequent use of preoperative chemotherapy. The comorbidity score and treatment at a nonacademic hospital were also associated with less frequent use of preoperative chemotherapy use, but these factors were not associated with a race/ethnicity that was not NH white.
After propensity-score matching, a total of 8016 patients were matched (4008 in each group). Conditional Original Article logistic regression showed that race/ethnicity other than NH white race was associated with less frequent use of preoperative chemotherapy (odds ratio, 0.77; 95% CI, 0.68-0.87; P < .001), and this was consistent with the original logistic regression models described previously (Supporting Information 3 [see online supporting information]).
Survival Analyses
The vital status was available for 14,626 patients, of whom 6367 (44%) were dead at the last follow-up. The median follow-up time was 1.97 years (interquartile range, 1.01-3.59 years). The median survival length was 4.11 years (95% CI, 4.04-4.20 years), the 2-year OS rate was 86.5% (95% CI, 85.9%-87.1%), and the 5-year OS rate was 55.8% (95% CI, 54.9%-56.7%). Interaction terms between race/ethnicity and preoperative therapy regimen had a P value < .001 according to a likelihoodratio test; therefore, the model was stratified by preoperative therapy regimen. A Cox regression model including only patients who had undergone surgical resection without preoperative chemotherapy showed significant racial/ ethnic disparities, whereas there was no difference in OS between racial/ethnic groups for patients who had undergone preoperative chemoradiation therapy (Table 3 and Fig. 3 ). 
Short-Term Outcomes
Patients who underwent preoperative chemotherapy had pathologic T0 (12%) and N0 disease (49%) more frequently than patients who did not (pT0 in 0.5% and pN0 in 34%; P < .001 for each), even though their tumors were more clinically advanced at presentation; this difference indicates the effectiveness of the preoperative therapy (Supporting Table 1 [see online supporting information]). According to multiple logistic regression, preoperative chemotherapy use was associated with a shorter hospital stay (14 days; odds ratio, 0.82; 95% CI, 0.74-0.91; P < .001) and a lower incidence of 30-day readmission (odds ratio, 0.86; 95% CI, 0.74-0.99; P 5 .048). Preoperative chemotherapy use was not associated with lower 90-day mortality (odds ratio, 0.93; 95% CI, 0.80-1.08; P 5 .329; Supporting Table 2 [see online supporting information]).
DISCUSSION
This retrospective cohort study using the NCDB affirmed trends and revealed racial/ethnic disparities in preoperative chemotherapy use and outcomes in patients with gastric cancer. First, a descriptive analysis showed a remarkable trend of increasing preoperative chemotherapy use for gastric cancer in the United States. Second, the frequency of preoperative chemotherapy use was very high for cardia tumors, whereas it was not as high for noncardia tumors, although a trend of increasing use was observed in both location categories. Third, race/ethnicity other than NH white race was independently associated with less frequent use of preoperative chemotherapy in patients with gastric cancer, particularly NH blacks and APIs. Fourth, no insurance status and a low education level (as a surrogate marker of socioeconomic status) mediated an enhanced effect of racial/ethnic disparity in preoperative chemotherapy use in patients with gastric cancer. Last, the use of preoperative chemotherapy and radiation therapy was associated with reduced racial/ethnic disparities in OS.
Racial disparities in cancer outcomes in the United States have been reported previously. 1, [18] [19] [20] Nonwhite populations, especially African Americans, are more susceptible to a poor presentation and worse outcomes with cancer. 1 The racial disparity in cancer outcomes is caused by patient factors such as comorbidities, differences in tumor biology, and, more importantly, unequal access to optimal cancer care, such as cancer prevention, early detection, and high-quality treatment. 1, 19, 20 Improving racial disparities in access to high-quality cancer care is an important public health challenge in the United States, particularly for patients with gastric cancer. 3 A trend of increasing preoperative chemotherapy use in patients with gastric cancer in the United States has been previously reported, 12 but the authors of that study did not assess the impact of race or the location of the primary tumor on preoperative chemotherapy use; this motivated us to conduct the current study. Our study revealed that the high frequency of preoperative chemotherapy use in patients with gastric cancer in recent years was driven mainly by its use in patients with cardia tumors. Notably, preoperative chemotherapy and radiation therapy are an established standard treatment for esophageal or gastroesophageal cancers. 21, 22 The proportion of gastroesophageal junction invasion among patients with cardia tumors in this study is unknown because this variable is not reported in the NCDB, but our study indicated that cardia tumors are treated much as gastroesophageal tumors are. The use of preoperative chemotherapy in patients with noncardia gastric cancer, even with the increase in preoperative chemotherapy use for gastric cancers as a whole, was not as common. These findings suggest that preoperative chemotherapy is not widely accepted as a standard therapy for noncardia gastric cancer in the United States, even though preoperative chemotherapy is recommended on the basis of results from randomized controlled tials. 9, 13 Complications from the primary tumor, such as bleeding and obstruction, which may be more common with noncardia tumors than cardia tumors, may have also contributed to the observed difference in preoperative chemotherapy use by tumor location. The use of preoperative chemotherapy was remarkably more common in academic cancer centers, and the trend of increasing preoperative chemotherapy use is expected to continue as further studies deepen our understanding of the benefits of preoperative therapy and its best regimens. 23 In addition to the finding that race/ethnicity other than NH white race was associated with less frequent use of preoperative chemotherapy, we found that a low education level and a no-insurance status mediated the enhanced effect of racial/ethnic disparities in preoperative chemotherapy use. We also observed a significant racial/ ethnic disparity in OS, and preoperative chemotherapy and radiation therapy use was associated with a significant reduction in this disparity. Our study highlighted the importance of insurance in enabling access to high-quality gastric cancer treatment in the United States. Future interventions to equalize access to high-quality care for gastric cancer among racial groups should include the development of more commonly available public health insurance systems to support patients of racial minorities in the United States.
This study has some limitations. Its retrospective nature produces an inherent selection bias. Although approximately 70% of all newly diagnosed cases of cancer in the United States are reported to the NCDB, the NCDB collects data only from Commission on Cancer-accredited hospitals. The access to those accredited hospitals is likely not equal for all racial/ethnic groups; therefore, the study results may have underestimated the racial/ethnic disparity. We included only patients who had clinical T category information, which may also be affected by a selection bias. The inability to review individual medical records to check for accuracy was also a limitation of using the NCDB. Another limitation was missing information, which included the performance status, intolerance to chemotherapy, and emergent surgery, any of which may have affected the decision to use preoperative chemotherapy. The survival benefit and the optimal regimens of preoperative therapy need to be determined by prospective trials. However, using a high-quality national database with a large number of patients is likely the most effective and efficient method for investigating racial disparities in gastric cancer treatment.
In conclusion, racial/ethnic disparities exist in preoperative chemotherapy use and outcomes for patients with gastric cancer in the United States. Race was independently associated with a low frequency of preoperative chemotherapy use after adjustments for patient, disease, and hospital factors. The frequency of preoperative chemotherapy use was low for noncardia tumors, although preoperative chemotherapy was more commonly used at academic cancer centers, and its use increased over time. Preoperative chemotherapy and radiation therapy use was associated with reduced racial/ethnic disparities in OS. This study is the first to examine racial/ethnic disparities in the use of preoperative chemotherapy for gastric cancer, and we hope that the results will guide future interventions to equalize access to high-quality care for patients with gastric cancer in the United States.
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